Skip to main content

Table 1 The clinical and laboratory features of patients with both cognitive impairment and cancer

From: Association between cognitive impairment patient with solid cancer and insulin resistance

Age Gender Cognitive impairment Cancer BS IRI IR %B
80s–90s M Alzheimer Esophagus 204 6.1 0.95 16.5
80s–90s M Alzheimer Stomach 192 11.6 1.77 30
80s–90s F Cerebrovascular Stomach 213 12.2 1.91 26
70s–80s F Cerebrovascular Colon 190 11.9 1.81 31.1
90s–100s M Cerebrovascular Colon 273 10.4 1.91 15.1
80s–90s M Alzheimer Colon 195 8.5 1.31 23
80s–90s F Alzheimer Pancreas 318 10.3 2.38 11.8
80s–90s M Alzheimer Bile duct 191 11.2 1.71 29.4
90s–100s M Cerebrovascular Prostate 220 13.3 2.1 26.3
70s–80s F Alzheimer Breast 110 12.7 1.72 90.4
90s–100s M Alzheimer Lung 198 16.3 2.48 37
80s–90s F Parkinson Ovary 200 15.4 2.35 34.8
70s–80s F Alzheimer Vulvar 275 12.2 2.25 17
  1. BS blood sugar (mg/dL), IRI insulin (μU/mL), IR Homeostatic Model Assessment of Insulin Resistance (HOMA-IR), %B Homeostatic Model Assessment of β-cell Function (HOMA-B) (%)